Recent Updates
Recently added Catalysts
ATHE

Appendix 3Z Final Director's Interest Notice Rule 3.19A.3 Appendix 3Z Final Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given

Key Takeaway: Director's Interest Notice Director's Interest Notice or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Name of entity Alterity Therapeutics Limited (ASX: ATH) ABN 37

Full Press Release Details

Director's Interest Notice
Director's Interest Notice
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property
and may be made public.
Name of entity Alterity Therapeutics Limited (ASX: ATH)
ABN 37 080 699 065
(the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section
205G of the Corporations Act.
Name of director Dr. David Sinclair
Date of last notice 21st September 2020
Date that director ceased to be director 4th January 2022
1 - Director's relevant interests in securities of which the director is the registered holder
the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director"
should be disclosed in this part.
& class of securities
options over ordinary shares issued under 2018 ADS ESOP Plan with exercise price of $0.09 each expiring 17/09/2025 have been forfeited
+ See chapter 19 for defined terms.
Director's Interest Notice
2 - Director's relevant interests in securities of which the director is not the registered holder
In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director"
should be disclosed in this part.
the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
3 - Director's interests in contracts
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
No. and class of securities to which interest relates N/A
+ See chapter 19 for defined terms.
Director's Interest Notice
Director's Interest Notice
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property
and may be made public.
Name of entity Alterity Therapeutics Limited (ASX: ATH)
ABN 37 080 699 065
(the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section
205G of the Corporations Act.
Name of director Tristan Edwards
Date of last notice 21st September 2020
Date that director ceased to be director 4th January 2022
1 - Director's relevant interests in securities of which the director is the registered holder
the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director"
should be disclosed in this part.
& class of securities
options over ordinary shares issued under 2018 ADS ESOP Plan with exercise price of $0.09 each expiring 17/09/2025 have been forfeited
+ See chapter 19 for defined terms.
Director's Interest Notice
2 - Director's relevant interests in securities of which the director is not the registered holder
In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director"
should be disclosed in this part.
the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
3 - Director's interests in contracts
Detail of contract N/A
Nature of interest N/A
Name of registered holder (if issued securities) N/A
No. and class of securities to which interest relates N/A
+ See chapter 19 for defined terms.
Last updated: Jan 5, 2022